Wolf J, Souquet PJ, Goto K, Cortot A, Baik C, Heist R, Kim TM, Han JY, Neal JW, Mansfield AS, Gilloteau I, Nwama N, Waldron-Lynch M, Davis KL, Giovannini M, Awad MM. Improved survival outcomes in patients with MET-dysregulated advanced NSCLC treated with MET inhibitors: results of a multinational retrospective chart review. Clin Lung Cancer. 2023 Nov;24(7):641-650.e. doi: 10.1016/j.cllc.2023.08.011
Wong-Sefidan I, Byrtek M, Zhou X, Dawson K, Friedberg J, Flowers CR, Zelenetz A, Reid E. Non-clinical factors drive imaging patterns after induction therapy of follicular lymphoma (FL): report from the National LymphoCare Study (NLCS). Poster presented at the 2013 12th International Conference on Malignant Lymphoma; June 2013. Lugano, Switzerland. [abstract] Hematol Oncol. 2013 Jun 17; 31(S1):255.
Feltner D, Hill C, Lenderking W, Williams VS, Morlock R. Development of a patient-reported assessment to identify placebo responders in a generalized anxiety disorder trial. J Psychiatr Res. 2009 Oct;43(15):1224-30.
Morlock RJ, Williams VS, Cappelleri JC, Harness J, Fehnel SE, Endicott J, Feltner D. Development and evaluation of the Daily Assessment of Symptoms – Anxiety (DAS-A) Scale to evaluate onset of symptom relief in patients with generalized anxiety disorder. J Psychiatr Res. 2008 Oct;42(12):1024-36.
Soni MK, Cella D, Masters GA, Burch SP, Heyes AE, Silberman C. The validity and clinical utility of symptom monitoring in advanced lung cancer: a literature review. Clin Lung Cancer. 2002 Nov;4(3):153-60.